Fig. 1 · Structure

Documents & Downloads

PD 123319 ditrifluoroacetate

Cat. No. A13201 CAS 136676-91-0

angiotensin AT2 receptor antagonist

PD 123319 ditrifluoroacetate is a potent, selective, non-peptide angiotensin AT2 receptor antagonist. IC50 values are 34 and 210 nM in rat adrenal tissue and brain respectively.

In Stock

Publications for PD 123319 ditrifluoroacetate

1 publication citing this product

  1. Dao-Lai Zhang, .et al. , eLife, 2018, 7: e33432 PMID: 29393851

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Bioactivity / Mechanism

PD123319 ditrifluoroacetate is used as an angiotensin II AT2 receptor antagonist. In a mouse joint-challenge study, local coadministration opposed angiotensin II-induced nociception. Its effects require model-specific interpretation: during angiotensin II infusion in hypercholesterolemic mice, PD123319 increased measured suprarenal aortic expansion even in the absence of AT2 receptors. [1,2]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Target & Activity

Target Activity Value
AT2 receptor 34 nM

PD 123319 ditrifluoroacetate Research Summary

This section summarizes 3 in vivo studies of PD 123319 ditrifluoroacetate from 2 published references.

PD 123319 ditrifluoroacetate In Vivo Studies

In male mice, intra-articular PD123319 ditrifluoroacetate coadministered with monosodium urate crystals reduced nociceptive responses at 4 h and inhibited ankle edema. These findings describe an acute preventive coadministration model. [1]

During angiotensin II infusion in male LDL receptor-deficient mice, PD123319 increased ex vivo suprarenal aortic width in surviving AT2-intact and AT2-deficient animals. It did not significantly alter aortic arch area, atherosclerotic lesion area or systolic blood pressure under these conditions. [2]

Local PD123319 in an acute MSU joint-pain model

Animal study · Adult male C57BL/6/J/UFU mice, 20–25 g; local joint challenge. [1]

Coadministration reduced pain responses and ankle edema in the acute MSU model. Selected pain comparisons are at 4 h, where the viewed plots show drug-versus-MSU significance. This is prevention by coadministration, not reversal of established disease.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Mechanical allodynia, spontaneous nociception and cold nociceptive responses at 4 hDirection versus MSU alone Reduced; n = 6 mice/group; plotted summaries mean ± SEM.[1]
Ankle articular edema at 4 hReported inhibition 45.4±6.8 % of control; n = 5 mice/group.[1]

Conditions shared by the study groups

Route
Intra-articular
Frequency
Once, coadministered
Treatment course
One challenge; pain followed to 24 h, edema at 4 h
Vehicle
PBS
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
PD123319 + MSU
PD123319 10 pmol/joint; MSU 100 μg/joint
MSU alone and vehicle-injected mice.Pain measures lower than MSU alone at 4 h; ankle edema inhibited.[1]
PD123319 + MSU
Model: Adult male C57BL/6/J/UFU mice, 20–25 g; local joint challenge.
Methods and source locations

Compound reported in the paper: PD123319 ditrifluoroacetate; Compound label in the paper: Tocris Bioscience 1361; batch 3A/189254

Reported Tocris salt in male mice; results do not validate an Adooq lot or establish clinical efficacy.

Methods 2.1–2.5, 2.8; Results 3.1–3.2; Figure 1A–C and Figure 2A.

Mechanical allodynia, spontaneous nociception and cold nociceptive responses at 4 h: Von Frey threshold, weight-bearing nociception score and acetone-evoked cold response. — Methods 2.4, 2.8; Results 3.1; Figure 1A–C and caption.

Ankle articular edema at 4 h: Plethysmometry; authors report percentage inhibition in Results 3.2. Statistical reporting: mean ± SEM. — Methods 2.5, 2.8; Results 3.2; Figure 2A and caption.

PD123319 + MSU · Methods 2.2–2.5; Figure 1A–C; Figure 2A.

PD123319 opposes local angiotensin II nociception

Animal study · Adult male C57BL/6/J/UFU mice, 20–25 g; local joint challenge. [1]

At 4 h, PD123319 coadministration prevented the mechanical allodynia caused by local angiotensin II and reduced spontaneous and cold nociceptive responses. This functional challenge supports its use as an angiotensin receptor antagonist in this model; it is not a binding/selectivity measurement.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Angiotensin II-evoked mechanical, spontaneous and cold nociceptive responses at 4 hFunctional antagonism Mechanical allodynia prevented; spontaneous and cold responses reduced; n = 6 mice/group; mean ± SEM.[1]

Conditions shared by the study groups

Route
Intra-articular
Frequency
Once, coadministered
Treatment course
One challenge; behavior followed through 24 h; selected result at 4 h
Vehicle
PBS
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
PD123319 + angiotensin II
PD123319 10 pmol/joint; angiotensin II 0.5 nmol/joint
Angiotensin II alone and vehicle-injected mice.Antagonized the 4-h nociceptive response.[1]
PD123319 + angiotensin II
Model: Adult male C57BL/6/J/UFU mice, 20–25 g; local joint challenge.
Methods and source locations

Compound reported in the paper: PD123319 ditrifluoroacetate; Compound label in the paper: Tocris Bioscience 1361; batch 3A/189254

Reported Tocris salt in male mice; results do not validate an Adooq lot or establish clinical efficacy.

Methods 2.1–2.4, 2.8; Results 3.3; Figure 3B–D and caption.

Angiotensin II-evoked mechanical, spontaneous and cold nociceptive responses at 4 h: Von Frey threshold, weight-bearing score and acetone-evoked cold response. — Methods 2.4, 2.8; Results 3.3; Figure 3B–D.

PD123319 + angiotensin II · Methods 2.2–2.4; Results 3.3; Figure 3B–D.

AT2-independent increase in aortic expansion during angiotensin II infusion

Animal study · Male LDL receptor-deficient mice on a saturated-fat-enriched diet, with wild-type (AT2 +/y) or deficient (AT2 −/y) AT2 receptor genotype. [2]

Among surviving mice evaluated ex vivo, PD123319 increased suprarenal aortic width during AngII infusion in both AT2 genotypes, indicating that this measured expansion does not require AT2 receptors. Aortic arch area, atherosclerotic lesion area and systolic blood pressure did not change significantly with the drug. Mortality and aneurysm-incidence claims are excluded because rupture denominators are unclear.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Ex vivo maximal suprarenal aortic width in surviving animalsDrug effect Increased with PD123319; P = 0.01; no significant genotype effect.[2]
Aortic arch intimal area, atherosclerotic lesion area and systolic blood pressureReported null comparisons No significant PD123319 effects in either genotype.[2]

Conditions shared by the study groups

Route
Subcutaneous osmotic minipump
Frequency
Continuous
Treatment course
4 weeks
Vehicle
Saline reported; distinct drug stock vehicle unspecified
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
AngII + PD123319, AT2 +/y
PD123319 3 mg/kg/d; angiotensin II 500 ng/kg/min
Angiotensin II alone in the same genotype.Increased ex vivo suprarenal aortic width in surviving mice; no significant changes in arch area, atherosclerosis or systolic pressure. Incidence and mortality claims excluded.[2]
AngII + PD123319, AT2 −/y
PD123319 3 mg/kg/d; angiotensin II 500 ng/kg/min
Angiotensin II alone in the same genotype.Increased ex vivo suprarenal aortic width in surviving mice; no significant changes in arch area, atherosclerosis or systolic pressure. Incidence and mortality claims excluded.[2]
AngII + PD123319, AT2 +/y
Model: Male LDL receptor-deficient mice on a saturated-fat-enriched diet, with wild-type (AT2 +/y) or deficient (AT2 −/y) AT2 receptor genotype. Selected genotype: AT2 +/y
Reported limits: Animal age and historical drug batch not reported in the read methods; mortality/endpoint denominators are not combined into a new estimate.
AngII + PD123319, AT2 −/y
Model: Male LDL receptor-deficient mice on a saturated-fat-enriched diet, with wild-type (AT2 +/y) or deficient (AT2 −/y) AT2 receptor genotype. Selected genotype: AT2 −/y
Reported limits: Animal age and historical drug batch not reported in the read methods; mortality/endpoint denominators are not combined into a new estimate.
Methods and source locations

Compound reported in the paper: PD123319; Compound label in the paper: Sigma-Aldrich P186

Published Sigma P186 result in surviving male AngII/LDLR-deficient mice; evidence of an AT2-independent measured aortic expansion response, without a mortality or aneurysm-incidence conclusion.

Materials and Methods: Mice and Diets, minipump implantation, endpoint quantification and statistics; Results drug-co-infusion subsection; Figures 4–6; Table 2; Figure S1.

Ex vivo maximal suprarenal aortic width in surviving animals: Two-way ANOVA; individual animals, group means ± SEM shown. — Results: PD123319 Augmented AngII-induced AAAs Independent of AT2 Receptor Genotype; Figure 4A and caption.

Aortic arch intimal area, atherosclerotic lesion area and systolic blood pressure: En face area measurements and tail-cuff blood pressure; two-way ANOVA and repeated-measures ANOVA, respectively. — Results drug-co-infusion subsection; Figures 5–6 and captions; Table 2 and footnotes.

AngII + PD123319, AT2 +/y · Methods minipump/diet sections; Results drug-co-infusion subsection; Figures 4–6; Table 2.

AngII + PD123319, AT2 −/y · Methods minipump/diet sections; Results drug-co-infusion subsection; Figures 4–6; Table 2.

Specifications

Manufacturer Adooq Bioscience
Actions Antagonist
CAS Number 136676-91-0
Alternate CAS 130663-39-7
Applications angiotensin AT2 receptor antagonist
Formula C31H32N4O3.2CF3CO2H
Molecular Weight 736.67
Synonyms PD123319
SMILES
CC1=C(C=CC(=C1)CN2C=NC3=C2CC(N(C3)C(=O)C(C4=CC=CC=C4)C5=CC=CC=C5)C(=O)O)N(C)C.C(=O)(C(F)(F)F)O.C(=O)(C(F)(F)F)O

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 87 mg/mL (171.05 mM)
Water 87 mg/mL (171.05 mM)
Ethanol 87 mg/mL (171.05 mM)

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

In Vivo Preparation

Concentration
28 mg/mL
Vehicle
Saline

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

PD 123319 ditrifluoroacetate Research References

  1. [1] Thiago Neves Vieira, André L Lopes Saraiva, Rafaela Mano Guimarães, et al. Angiotensin type 2 receptor antagonism as a new target to manage gout Inflammopharmacology (2022). PMID: 36173505 DOI: 10.1007/s10787-022-01076-x Source material
  2. [2] Alan Daugherty, Debra L. Rateri, Deborah A. Howatt, et al. PD123319 Augments Angiotensin II-Induced Abdominal Aortic Aneurysms through an AT2 Receptor-Independent Mechanism PLoS ONE (2013). PMID: 23593499 DOI: 10.1371/journal.pone.0061849 Source material

Publications

1 publication citing this product

  1. Dao-Lai Zhang, .et al. , eLife, 2018, 7: e33432 PMID: 29393851

Added to your cart

View Cart Checkout
Loading...